In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation 1

Journal of Immunology

Volumn 157, Issue 7, 1996, Pages 3165-3170

  Harvill, Eric T ^a   Fleming, Jennifer M ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DANSYL CHLORIDE; HAPTEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; SEPHAROSE;

ANIMAL; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; FEMALE; HALF LIFE TIME; IMMUNIZATION; IMMUNOLOGY; MOUSE; TISSUE DISTRIBUTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DANSYL COMPOUNDS; FEMALE; HALF-LIFE; HAPTENS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SEPHAROSE; SERUM ALBUMIN, BOVINE; TISSUE DISTRIBUTION;

EID: 0030267660     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lotze, M. T., Y. L. Matory, S. E. Ettinghausen, A. A. Rayner, S. O. Sharrow, C. A. Seipp, M. C. Custer, and S. A. Rosenberg. 1985. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135:2865.
2. Donohue, J. H., and S. A. Rosenberg. 1983. The fate of interleukin-2 after in vivo administration. J. Immunol. 130:2201.
3. Anderson, P. M., E. Katsanis, S. F. Sencer, D. Hasz, A. C. Ochoa, and B. Bostrom. 1992. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J. Immunother. 12:19.
4. Nakao, M., M. Hazama, A. Mayumi-Aono, S. Hinuma, and Y. Fujisawa. 1994. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein J. Infect. Dis. 169:787.
5. Chen, T. T., M. H. Tao, and R. Levy. 1994. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153:4775.
6. Hazama, M., A. Mayumi-Aono, N. Asakawa, S. Kuroda, S. Hinuma, and Y. Fujisawa. 1993. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 11:629.
7. Hazama, M., A. Mayumi-Aono, T. Miyazaki, S. Hinuma, and Y. Fujisawa. 1993. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 78: 643.
8. Hinuma, S., M. Hazama, A. Mayumi, and Y. Fujisawa. 1991. A novel strategy for converting recombinant viral protein into high immunogenic antigen. FEBS Lett. 288:138.
9. Harvill, E. T., and S. L. Morrison. 1995. An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1:95.
10. Amigorena, S., C. Bonnerot, W. H. Fridman, and J. L. Teillaud. 1990. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. Eur. J. Immunol. 20:1781.
11. Morrison, S. L., L. A. Wims, and V. T. Oi. 1988. Genetically engineered antibody molecules: new tools for cancer therapy. Cancer Invest. 6:185.
12. Shin, S. U., and S. L. Morrison. 1989. Production and properties of chimeric antibody molecules. Methods Enzymol. 178:459.
13. Zuckier, L. S., L. Georgescu, C. J. Chang, M. D. Scharff, and S. L. Morrison. 1994. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 73:794.
14. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595.
15. 2 fragments against idiotypic determinants of its cell surface IgM. J. Immunol. 131:1600.
16. Gillies, S. D., D. Young, K. M. Lo, and S. Roberts. 1993. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug. Chem. 4:230.
17. Murray, H. W., K. Welte, J. L. Jacobs, B. Y. Rubin, R. Mertelsmann, and R. B. Roberts. 1985. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J. Clin. Invest. 76:1959.
18. Kovacs, J. A., M. Baseler, M. Dewar, S. Vogel, R. T. Davey, Jr., J. Falloon, M. A. Polis, R. E. Walker, R. Stevens, N. P. Salzman, J. A. Metcalf, H. Masur, and H. C. Lane. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N. Engl. J. Med. 332:567.
19. Phillips, M. L., M. H. Tao, S. L. Morrison, and V. N. Schumaker. 1994. Human/ mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol. Immunol. 31:1201.
20. Gillies, S. D., E. B. Reilly, K. M. Lo, and R. A. Reisfeld. 1992. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89:1428.
21. Sabzevari, H., S. D. Gillies, B. M. Mueller, J. D. Pancook, and R. A. Reisfeld. 1994. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad Sci. USA 91:9626.
22. Becker, J. C., J. D. Pancook, S. D. Gillies, M. Mendelsohn, and R. A. Reisfeld. 1996. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA 93:2702.